Bailard’s Zymeworks ZYME Stock Holding History

Bailard’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-73,200	Closed	-$2.13M	–	794
2021 Q3	$2.13M	Sell	73,200 -16,500	-18%	-$549K	0.07%	195
2021 Q2	$3.11M	Buy	89,700 +26,200	+41%	+$831K	0.11%	158
2021 Q1	$2M	Buy	+63,500	New	+$2.58M	0.07%	201

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bailard's ZYME Position: Q4 2021 in Review

Bailard sold out of Zymeworks (ZYME) in Q4 2021, closing a stake of 73,200 shares — an estimated $2.13M sold.

Bailard first reported a position in ZYME in Q1 2021 and held it in 3 quarters. The position peaked at $3.11M in Q2 2021. 114 funds tracked by Wall St. Rank hold ZYME as of Q4 2021.

Bailard reported no remaining Zymeworks position as of Q4 2021 after selling out during the quarter.
Bailard sold 73,200 Zymeworks shares in Q4 2021, an estimated $2.13M.
Bailard first reported a position in Zymeworks in Q1 2021 and held it in 3 quarters.
Bailard's Zymeworks position peaked at $3.11M in Q2 2021.
114 funds tracked by Wall St. Rank held Zymeworks as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.